A ‘real‐world’ retrospective multi‐centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis
Open Access
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designsExpert Review of Gastroenterology & Hepatology, 2015
- Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysisJournal of Crohn's and Colitis, 2014
- Biological Agents for Moderately to Severely Active Ulcerative ColitisAnnals of Internal Medicine, 2014
- Systematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitisAlimentary Pharmacology & Therapeutics, 2014
- Systematic Assessment of Factors Influencing Preferences of Crohnʼs Disease Patients in Selecting an Anti-Tumor Necrosis Factor Agent (CHOOSE TNF TRIAL)Inflammatory Bowel Diseases, 2012
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut, 2011
- Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximabAlimentary Pharmacology & Therapeutics, 2010
- Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohortAlimentary Pharmacology & Therapeutics, 2010
- Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or InfliximabGastroenterology, 2009
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005